One of ProStrakan's primary strengths is in its multidisciplinary staff of about 35 development professionals whose expertise covers all aspects of research and development with experience gained in the US, Europe and Japan as well as in both big pharma and biotech environments. The development function is based at Galashiels in Scotland and in Bedminster, New Jersey, USA.

ProStrakan's development management team has a significant track record of success including approvals for Adcal D3, Tostran, Rectogesic, Xomolix, Abstral and Sancuso.